Leiden, The Netherlands - AVIGI Therapeutics, a biotech company dedicated to transforming how diabetic kidney disease is treated strengthens chemistry alliance with Leiden University. We have been awarded the "Inzetproject PPS-i-toeslag" from TKI Groene Chemie (Top Consortium for Knowledge and Innovation Green Chemistry). This grant, which will fuel our research efforts throughout 2026, marks a step forward and underscores the power of strategic scientific partnerships in driving tangible therapeutic impact.
This achievement is not ours alone. We are proud to share this success with our esteemed roots at Leiden University, specifically the renowned research group led by our scientific advisor, Professor Hermen Overkleeft. This collaboration brings together AVIGI’s innovative approach to drug development with the world-class bio-organic chemistry expertise of Leiden University.
Advancing VL166: Synthesis, Analysis, and Process
The TKI Groene Chemie grant is designed to boost public-private partnerships that drive innovation in sustainable and green chemistry. For AVIGI, this funding is a critical catalyst for the next phase of development for our lead asset, VL166, a first-in-class covalent inhibitor of heparanase.
Welcoming Top-Tier Talent: Dr. Helena Ehren Joins AVIGI
Executing on such an ambitious scientific vision requires a world-class team. As part of our commitment to attracting top-tier talent to drive these initiatives, we are incredibly proud to welcome Dr. Helena Ehren to AVIGI Therapeutics.
Bringing a wealth of expertise in complex organic synthesis and chemical biology, Dr. Ehren is perfectly positioned to help advance our goals. She will be jointly working on this TKI-funded project, serving a vital dual role between AVIGI and Leiden University. With her highly specialized background and deep understanding of the sophisticated chemistry required for our compound class, Dr. Ehren will work directly alongside Professor Overkleeft’s group and within AVIGI Therapeutics. Her involvement on this joint initiative ensures a seamless, highly productive collaboration as we optimize the synthesis and analytical development of VL166.
Stay Connected with Our Progress
We are incredibly energised by the opportunity to deepen our collaboration with Leiden University. Keep an eye on our blog for regular updates on the VL166 program, our ongoing research, and upcoming career opportunities. The future of chemistry-driven therapeutics is bright, and at AVIGI, we are proud to be at the forefront alongside the best and brightest in the field.